ロード中...
Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
The treatment of advanced triple-negative breast cancer, which failed in first-line or second-line therapy, is a significant challenge. We conducted this retrospective study to explore the efficacy and safety of apatinib and capecitabine as the third-line treatment for advanced triple-negative breas...
保存先:
| 出版年: | Medicine (Baltimore) |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6133618/ https://ncbi.nlm.nih.gov/pubmed/30200142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000012222 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|